Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.58 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11074941 | 0.80 | PDCD1 (0.69) | CD274PDCD1CYP2A6EPHX1CYP11B1 | |
| SCHEMBL30091380 | 0.80 | PDCD1 (0.69) | CD274PDCD1CYP2A6EPHX1CYP11B1 | |
| SCHEMBL18367730 | 0.77 | CD274 (0.70) | CD274PDCD1EPHX1S1PR1S1PR3 | |
| SCHEMBL29558512 | 0.75 | CD274 (1.00) | CD274PDCD1EPHX1 | |
| SCHEMBL358303 | 0.75 | CD274 (1.00) | CD274PDCD1EPHX1 | |
| SCHEMBL12577749 | 0.74 | CYP2A6 (0.54) | CYP2A6CYP11B1CYP11B2S1PR1PRKCI | |
| SCHEMBL16245269 | 0.74 | PDCD1 (0.76) | CD274PDCD1EPHX1S1PR1S1PR3 | |
| SCHEMBL21130363 | 0.72 | PDCD1 (0.58) | CD274PDCD1CYP2A6S1PR1S1PR3 | |
| SCHEMBL21130586 | 0.71 | PDCD1 (0.53) | CD274PDCD1CYP11B1CYP11B2S1PR1 | |
| SCHEMBL21130599 | 0.71 | PDCD1 (0.53) | CD274PDCD1CYP11B1CYP11B2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| EP-3612525-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| CN-110799509-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2020-02-14 | — | — | CN | disclosed |
| WO-2018195321-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | CD274 1/4885PDCD1 2/4885CYP2A6 3980/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | CD274 1/4885PDCD1 3/4885CYP2A6 1049/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | CD274 1/4885PDCD1 2/4885CYP2A6 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.